No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Lasa Supergenerics Limited is an Indian-based company that specializes in the research, development, production, and commercialization of healthcare products for both animals and humans, primarily serving the domestic market in India. Its core offerings include a diverse portfolio of Active Pharmaceutical Ingredients (APIs). These encompass a wide range of compounds such as fenbendazole, toldimphos sodium, cyromazine, albendazole, rafoxanide, ornidazole, oxfendazole, closantel base, nitroxynil, halquinol, and oxyclozanide, among many others, including specific chemicals like 2,6-diiodo-4-nitrophenol. Beyond APIs, the company also manufactures essential animal feed ingredients, notably calcium iodate, and supplies reagents for therapeutic applications, such as potassium iodide. The company additionally engages in the export of its various products, extending its reach beyond national borders. Established in 2016, Lasa Supergenerics Limited maintains its headquarters in Ratnagiri, India.
lasalabs.comNo one on the platform currently holds LASA.BO.
No tracked institution reports a position in LASA.BO as of their last filing.
No one on the platform has traded LASA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -82.4% | -34.1% | ||||
| Profit Margin % | -135.6% | -40.1% | -18.8% | |||
| Free Cash Flow Margin % | 0.0% | -1.3% | 3.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $2.2B | +0.0% | $5.15 | $5.15–$5.15 | — | 1 |
| 2028 | $2.5B | +12.3% | $6.49 | $6.49–$6.49 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-25 | $1.32 | $-0.83 | -162.9% |
| 2026-02-11 | $1.32 | $-0.51 | -138.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LASA.BOLasa Supergenerics Limited | $6.27 | -4.86% | $319M | — |
| BACPHAR.BOBacil Pharma Limited | $19.33 | -4.97% | $277M | — |
| BALAXI.NSBalaxi Pharmaceuticals Limited | $23.50 | +1.64% | $1.3B | — |
| BIOFILCHEM.BOBiofil Chemicals and Pharmaceuticals Limited | $33.65 | -0.27% | $548M | — |
| BIOFILCHEM.NSBiofil Chemicals and Pharmaceuticals Limited |
| $33.70 |
| +0.15% |
| $548M |
| — |
| CHOKSI.BOChoksi Asia Limited | $220.95 | +2.98% | $1.3B | — |
| MEDICAPQ.BOMedi-Caps Limited | $26.03 | -8.92% | $325M | — |
Source: Financial Modeling Prep · peers by sector/industry